Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21733005 | 0.82 | POLB (0.34) | EHMT2MEN1KMT2APKM | |
| SCHEMBL21723726 | 0.80 | TERT (0.39) | KMT2ASMN1; SMN2BACE1 | |
| SCHEMBL21723944 | 0.75 | GBA1 (0.38) | EGFR | |
| SCHEMBL20475932 | 0.70 | MMP1 (0.37) | MEN1KMT2ASMN1; SMN2EGFR | |
| SCHEMBL204489 | 0.70 | ADORA3 (0.49) | HTTMEN1KMT2ACSNK1DADORA3 | |
| SCHEMBL21723986 | 0.68 | IRAK4 (0.40) | EGFR | |
| SCHEMBL16709304 | 0.68 | ADORA3 (0.47) | HTTMEN1KMT2ACSNK1DADORA3 | |
| SCHEMBL3861813 | 0.67 | ALDH1A1 (0.42) | HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5146641 | 0.67 | ALDH1A1 (0.49) | HTTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL16632075 | 0.67 | ALDH1A1 (0.60) | HTTMEN1KMT2ATSHRPTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12201627-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-3837014-B1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20210308123-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2021-10-07 | — | — | US | disclosed |
| CN-113038989-A | Imidazo [4,5-C ] quinoline-derived NLRP3 modulators | 先天肿瘤免疫公司 | 2021-06-25 | — | — | CN | disclosed |
| EP-3837014-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | Innate Tumor Immunity, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020037091-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201627-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | EHMT2 4212/4885HTT 2959/4885MEN1 3081/4885 |
| US-20210308123-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | EHMT2 4212/4885HTT 2959/4885MEN1 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.